Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sing2016 M2SR H3N2 Influenza Vaccine in Older Adults
NCT04785794Phase 1Completed
- Sponsor
- FluGen
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of M2SR H3N2 influenza vaccine in influenza (4 arms), sponsored by FluGen. Primary endpoints: Treatment Emergent Adverse Events During 7 Days After Experimental Treatment, Treatment Emergent Adverse Events During 28 Days After Experimental Treatment and 1 more. Started Jun 2021; status: completed.
02
Drugs
M2SR H3N2 influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04785794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785794.